Related Experiment Video
Updated: Apr 26, 2026
02:47
Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
Published on: May 12, 2023
2.2K
Translating advances in cardiogenetics into effective clinical practice
Louise Bordeaux Silverstein1, Marina Stolerman2, Nadia Hidayatallah2
1Yeshiva University, Bronx, New York, USA louisesilverstein@gmail.com.
Qualitative Health Research
|August 13, 2014
Summary
Many patients struggle to understand genetic testing and cardiac disease information, leading to anxiety and confusion. Improving physician-patient communication is key for better care of genetic conditions.
Area of Science:
- Cardiology
- Genetics
- Medical Sociology
Background:
- Cardiogenetic disorders require complex genetic testing.
- Patient understanding and experience are crucial for effective management.
- Qualitative research can illuminate subjective patient experiences.
Purpose of the Study:
- To explore individuals' subjective experiences with genetic testing.
- To understand patient perspectives on cardiogenetic disorders.
- To identify barriers and facilitators in clinical care for these conditions.
Main Methods:
- Qualitative research study.
- Grounded theory approach.
- Analysis of interview and focus group transcripts from 50 participants.
Main Results:
- Nearly half of diagnosed participants had difficulty understanding genetic testing and cardiac disease information.
- Anxiety regarding testing and symptoms worsened cognitive confusion.
- Patient interactions with healthcare professionals varied based on provider knowledge.
Conclusions:
- Effective clinical care for genetic conditions faces significant barriers.
- Patient attitudes toward genetic testing are diverse (positive, negative, ambivalent).
- Enhanced collaborative decision-making between physicians and patients is recommended.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
119
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
119
01:29Cardiomyopathy V: Interprofessional Care
746
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
746
01:29Pharmacogenetics and Pharmacogenomics: Overview
241
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
241
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
801
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
801
01:30Cardiomyopathy II: Dilated Cardiomyopathy
785
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
785
01:25Cardiomyopathy I: Introduction and Classification
811
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
811